World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
72
Citations
24099
World Ranking
6175
National Ranking
471

Overview

Rab K. Prinjha is affiliated with GlaxoSmithKline in the United Kingdom. Their research primarily spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine. Within these broader fields, Prinjha's work has focused extensively on Molecular Biology, Hematology, Immunology, Virology, and Epidemiology.

The scientist's main research topics include Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Ubiquitin and proteasome pathways, Histone Deacetylase Inhibitors Research, HIV Research and Treatment, Epigenetics and DNA Methylation, and Immune cells in cancer.

Several recent papers illustrate the scope of Prinjha's research contributions:

  • "Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation," 2020, Science
  • "Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia," 2021, Nature Cancer
  • "Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism," 2020, Proceedings of the National Academy of Sciences
  • "GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins," 2020, Journal of Medicinal Chemistry
  • "Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening," 2020, Journal of Medicinal Chemistry

Frequent co-authors in Prinjha's publications include Inmaculada Rioja, Chun-wa Chung, Paul Bamborough, Emmanuel H. Demont, and Paola Grandi. These collaborations highlight sustained partnerships in producing research within their areas of study.

The venues where Prinjha has published most frequently consist of:

  • Journal of Medicinal Chemistry
  • bioRxiv (Cold Spring Harbor Laboratory)
  • ACS Medicinal Chemistry Letters
  • SSRN Electronic Journal
  • Proceedings of the National Academy of Sciences

Best Publications

  • Suppression of inflammation by a synthetic histone mimic

    Edwige Nicodeme;Kate L. Jeffrey;Uwe Schaefer;Soren Beinke

  • Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

    Mark A. Dawson;Rab K. Prinjha;Antje Dittmann;George Giotopoulos

  • Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways

    John P. Cogswell;James Ward;Ian A. Taylor;Michelle Waters

  • Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation

    Huw D Lewis;John Liddle;Jim E Coote;Stephen J Atkinson

  • Remodeling of the Enhancer Landscape during Macrophage Activation Is Coupled to Enhancer Transcription

    Minna U. Kaikkonen;Nathanael J. Spann;Sven Heinz;Casey E. Romanoski

  • Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease

    Hao Li;Sally Wetten;Li Li;Pamela L. St. Jean

  • Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis

    Sergio E. Baranzini;Joanne Wang;Rachel A. Gibson;Nicholas Galwey

  • Neuropilin-2 Is Required In Vivo for Selective Axon Guidance Responses to Secreted Semaphorins

    Roman J. Giger;Jean François Cloutier;Amar Sahay;Rabinder K. Prinjha

  • BET inhibitor resistance emerges from leukaemia stem cells

    Chun Yew Fong;Omer Gilan;Omer Gilan;Enid Y N Lam;Alan Rubin

  • An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

    Marian L. Burr;Marian L. Burr;Marian L. Burr;Christina E. Sparbier;Christina E. Sparbier;Kah Lok Chan;Kah Lok Chan;Yih-Chih Chan

  • Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

    Ariel Halper-Stromberg;Ching-Lan Lu;Florian Klein;Joshua A. Horwitz

  • Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

    Omer Gilan;Omer Gilan;Inmaculada Rioja;Kathy Knezevic;Matthew J. Bell

  • Discovery and Characterization of Small Molecule Inhibitors of the Bet Family Bromodomains.

    Chun-wa Chung;Hervé Coste;Julia H. White;Olivier Mirguet

  • Cloning and functional expression of a human orthologue of rat vanilloid receptor-1.

    Philip Hayes;Helen J Meadows;Martin J Gunthorpe;Mark H Harries

  • Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia

    Panagiotis Ntziachristos;Panagiotis Ntziachristos;Aristotelis Tsirigos;G. Grant Welstead;Thomas Trimarchi

  • Suppression of the antiviral response by an influenza histone mimic

    Ivan Marazzi;Jessica S. Y. Ho;Jaehoon Kim;Balaji Manicassamy

  • Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains

    Olivier Mirguet;Romain Gosmini;Jérôme Toum;Catherine A. Clément

  • Identification of a Novel Series of Bet Family Bromodomain Inhibitors: Binding Mode and Profile of I-Bet151 (Gsk1210151A).

    Jonathan Seal;Yann Lamotte;Frédéric Donche;Anne Bouillot

  • Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling

    Dan Levy;Alex J Kuo;Yanqi Chang;Uwe Schaefer

  • Place your BETs: the therapeutic potential of bromodomains

    R.K. Prinjha;J. Witherington;K. Lee

Frequent Co-Authors

Chun-wa Chung
Chun-wa Chung GlaxoSmithKline (United Kingdom)
David F. Tough
David F. Tough GlaxoSmithKline (United Kingdom)
Mark A. Dawson
Mark A. Dawson Peter MacCallum Cancer Centre
Alexander Tarakhovsky
Alexander Tarakhovsky Rockefeller University
Gerard Drewes
Gerard Drewes GlaxoSmithKline (United Kingdom)
Tony Kouzarides
Tony Kouzarides University of Cambridge
Udo Oppermann
Udo Oppermann University of Oxford
Susanne Müller
Susanne Müller Structural Genomics Consortium
Paul P. Tak
Paul P. Tak GlaxoSmithKline (United Kingdom)
Marcus Bantscheff
Marcus Bantscheff GlaxoSmithKline (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Rab K. Prinjha

Trending Scientists